Go to deals
Healthcare

AmeriCare Home Health has been acquired by Brooks Rehabilitation

The private shareholders of AmeriCare Home Health (AmeriCare) have sold the company to Brooks Rehabilitation. Financial details have not been disclosed.

AmeriCare is a leading provider of home healthcare services including skilled nursing, physical therapy, occupational therapy, speech therapy, social work, home health aide, and private duty. The company is headquartered in Jacksonville, Florida, and operates 10 satellite office locations serving 23 counties in northeast and central Florida.

Brooks Rehabilitation is a recognized leader in providing a system of world class rehabilitation services. It operates an inpatient hospital providing rehabilitation and medical care for people requiring intensive inpatient therapy, 26 outpatient clinics, as well as Brooks Home Care which serves northeast Florida.

Oaklins' team in Jacksonville acted as financial advisor and intermediary to the seller in this transaction.

Service
M&A sell-side
Parties

Talk to the deal team

 Asok K. Chaudhuri

Asok K. Chaudhuri

Principal

Jacksonville, United States
Oaklins Heritage
 Bill  Sorenson

Bill Sorenson

Principal

Jacksonville, United States
Oaklins Heritage
 Don  Wiggins

Don Wiggins

Principal

Jacksonville, United States
Oaklins Heritage

Related deals

Pridiktiv has been acquired by Corilus
Healthcare | TMT

Pridiktiv has been acquired by Corilus

The shareholders and founders of Pridiktiv NV have sold the company to Corilus.

Learn more
Global Media Santé has been acquired by SFP Expansion
Private Equity | Healthcare | TMT

Global Media Santé has been acquired by SFP Expansion

Global Media Santé’s CEO, Alain Trébucq, and Apax Partners have sold the company to SFP Expansion Group.

Learn more
Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Healthcare

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a Phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition the raise will be used to scale up manufacturing and device activities.

Learn more